Headquartered within the basic materials sector, Balchem Corporation focuses on Specialty Chemicals services and products. Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization,. Valued at $5.23B, BCPC is a mid-cap name in its sector. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Premium feature
News & analytics is part of Premium.
Every headline runs through our finance-grade sentiment engine, so you see the mood of the market on each ticker before you read a single article. Plus the full analyst consensus and target-price upside, refreshed daily.
Per-headline sentiment, scored by a finance-tuned model
See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.
The company holds $72.9M in cash, though total debt stands at $184.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $138.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 12.7% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $942.4M to $1.04B.
Investors considering Balchem Corporation should weigh the typical risks associated with BCPC's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Balchem Corporation's trajectory.